

OUR PIPELINE

We are advancing a diversified portfolio of product candidates derived from multiple platforms and are focused on immunotherapies for the potential treatment of cancer and mRNA vaccines to potentially prevent or treat infectious diseases.

Oncology

mRNA Cancer Immunotherapies

Platform	Product candidate	Target	Indication	Phase 1	Phase 1/2	Phase 2	Phase 3	BioNTech rights ⁽¹⁾	Collaborator/ Partner
FixVac	BNT111	NY-ESO-1, MAGE-A3, tyrosinase, TPTE	Advanced, R/R melanoma	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>		Fully owned ⁽²⁾	
	BNT113	E6, E7	Metastatic / R/R HPV16+ head and neck cancer ⁽⁵⁾	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>		
	BNT116	MAGE-A3, CLDN6, KK-LC-1, PRAME, MAGE-A4, MAGE-C1	1L metastatic NSCLC	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>			
iNeST	Autogene cevumeran (BNT122 / RO719845)	Patient-specific neoantigens	Advanced/metastatic NSCLC	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>		Collaboration	Genentech ⁽³⁾
			Adjuvant colorectal cancer	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>			
			Adjuvant muscle-invasive urothelial carcinoma	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>			
			Adjuvant pancreatic ductal adenocarcinoma	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>			
RiboCytokines	BNT152 + BNT153	IL-7, IL-2	Multiple solid tumors	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>		Fully owned	
			Multiple solid tumors	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>			

Next-generation Immunomodulators

Product candidate	Combination candidate	Target	Indication	Phase 1	Phase 1/2	Phase 2	Phase 3	BioNTech rights ⁽¹⁾	Collaborator/ Partner
BNT327		PD-L1 x VEGF-A	1L ES-SCLC	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>	Collaboration	Bristol Myers Squibb
			1L ES-SCLC ⁽⁴⁾	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>			
			1/2L+ ES-SCLC	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>			
			2L ES-SCLC ⁽⁴⁾	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>			
			2L SCLC ⁽⁴⁾	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>		
			1L NSCLC ⁽⁵⁾	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>			
			2L advanced/metastatic NSCLC	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>			
			2L+ EGFRm NSCLC ⁽⁴⁾	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>			
			1L advanced/metastatic TNBC ⁽⁴⁾	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>		
			1L advanced/metastatic TNBC ⁽⁴⁾	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>			
			1L/2L advanced/metastatic TNBC	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>			
			1L malignant pleural mesothelioma ⁽⁴⁾	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>			
			1L hepatocellular carcinoma ⁽⁴⁾	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>			
			2L neuroendocrine neoplasms ⁽⁴⁾	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>			
			Multiple solid tumors ⁽⁴⁾	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>			
	BNT3213	TIGIT x PVRIG	1L hepatocellular carcinoma ^(4, 6)	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>		Fully owned	
	Trastuzumab pamirtecane (BNT323 / DB-1303)	HER2	Advanced/metastatic breast cancer ⁽⁶⁾	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>		Collaboration	Duality Biologics
	BNT324 / DB-1311	B7-H3	Multiple solid tumors ⁽⁶⁾	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>			
	BNT325 / DB-1305	TROP2	Advanced/metastatic NSCLC and SCLC ⁽⁶⁾	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>			
BNT312 / GEN1042		CD40x4-1BB	Multiple solid tumors	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>		Collaboration	Genmab
BNT314 / GEN1059		EpCAMx4-1BB	Multiple solid tumors	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>			

Status: August 28, 2025

Golistobart (BNT316 / ONC-392)	CTLA-4	aPD(L)1-R/R metastatic NSCLC		Collaboration	OncoC4
		Platinum-resistant ovarian cancer			
		Metastatic castration-resistant prostate cancer			
		Multiple solid tumors			
BNT317	undisclosed	Multiple solid tumors		Fully owned	

Targeted Therapies

Platform	Product candidate	Target	Indication	Phase 1	Phase 1/2	Phase 2	Phase 3	BioNTech rights ⁽¹⁾	Collaborator/ Partner
Antibody-drug conjugates	Trastuzumab pamirtecán (BNT323 / DB-1303)	HER2	HR+/HER2-low metastatic breast cancer Multiple solid tumors					Collaboration	Duality Biologics
	BNT324 / DB-1311	B7-H3	Multiple solid tumors						
	BNT325 / DB-1305	TROP2	Multiple solid tumors						
	BNT326 / YL202	HER3	Multiple solid tumors						
Cell therapies	BNT211	CLDN6	Multiple solid tumors					Fully owned	MediLink Therapeutics

Infectious Diseases

Drug class	Product candidate	Indication	Phase 1	Phase 1/2	Phase 2	Phase 3	Commercial	BioNTech rights ⁽¹⁾	Collaborator/ Partner
mRNA	BNT162	COVID-19						Collaboration	Pfizer Fosun Pharma
	BNT162 + BNT161	COVID-19 – Influenza combination						Collaboration	Pfizer
	BNT163	HSV						Collaboration	University of Pennsylvania
	BNT164	Tuberculosis						Fully owned	Funded by the Gates Foundation
	BNT165	Malaria						Fully owned	
	BNT166	Mpox						Fully owned	Funded by CEP ⁽⁷⁾
Protein-based therapeutics	BNT331	Bacterial vaginosis						Fully owned	

BioNTech has refined the presentation of its pipeline chart this quarter to align more closely with its strategic priorities. As part of this update, programs that have been out-licensed or discontinued are no longer displayed on the pipeline chart. This adjustment is intended to provide a clearer and more focused representation of BioNTech's active pipeline of product candidates.

⁽¹⁾ For further details about BioNTech's rights, see quarterly reports on BioNTech's website.

⁽²⁾ The FixVac platform is fully owned by BioNTech. The BNT111 and BNT116 Phase 2 trials are jointly conducted with Regeneron as part of a cost-sharing strategic collaboration.

⁽³⁾ A member of the Roche group

⁽⁴⁾ Trial ongoing in China only

⁽⁵⁾ Part of a Phase 2/3 clinical trial

⁽⁶⁾ Trial is currently being conducted by or on behalf of BioNTech. Bristol Myers Squibb holds co-exclusive rights to BNT327.

⁽⁷⁾ Coalition for Epidemic Preparedness Innovations

Status: August 28, 2025